To appraise the clinical and cost effectiveness of dabrafenib in combination with trametinib within their marketing authorisations for adjunctive treatment of resected BRAF V600 mutation-positive malignant melanoma.
Status In progress
Process STA
ID number 1226

Provisional Schedule

Committee meeting: 1 19 July 2018
Committee meeting: 2 18 September 2018
Expected publication 26 December 2018

Project Team

Project lead Thomas Feist

Email enquiries


Key events during the development of the guidance:

Date Update
09 February 2018 Invitation to participate
02 October 2017 - 31 October 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
27 June 2017 In progress, Topic referred
19 September 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance